title: [New and emerging treatments for multiple sclerosis].
abstract: A number of disease-modifying therapies have been recently approved for the treatment of multiple sclerosis (MS). These molecules which prevent relapses and new central nervous system lesions are more efficient than the "old" first line therapies and/or more convenient, especially with oral agents. Their usefulness in treating active MS is undeniable, but we have to be aware of their potentially extremely severe side effects. The treatment algorithm in MS is constantly evolving according to the long term safety profile of these new treatments. A better knowledge of fundamental pathophysiology is associated with the development of new molecules targeting the immunological cascade of the disease as well as the mechanisms promoting remyelination and repair.
authors.affiliation: Département des maladies du système nerveux, Inserm 975, hôpital Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris Cedex 13, France.
authors.forename: Céline
authors.initials: C
authors.lastname: Louapre
authors.affiliation: Département des maladies du système nerveux, Inserm 975, hôpital Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris Cedex 13, France.
authors.forename: Élisabeth
authors.initials: É
authors.lastname: Maillart
authors.affiliation: Département des maladies du système nerveux, Inserm 975, hôpital Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris Cedex 13, France.
authors.forename: Caroline
authors.initials: C
authors.lastname: Papeix
authors.affiliation: Département des maladies du système nerveux, Inserm 975, hôpital Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris Cedex 13, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Lubetzki
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D009186:Myelin Sheath / Q000502:physiology; D055502:Secondary Prevention
chemical_list: D000911:Antibodies, Monoclonal; D007155:Immunologic Factors